A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT

Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality worldwide, accounting for an estimated 17.9 million deaths annually. Among the multiple risk factors for CVD, elevated lipoprotein(a) [Lp(a)] has emerged as a genetically determined and independent contributor to atherosclerosis, coronary artery disease, and thrombotic events. Structurally, Lp(a) consists of an LDL-like particle covalently linked to apolipoprotein(a) [apo(a)], which confers prothrombotic and pro-inflammatory properties. Elevated Lp(a) promotes plaque formation, arterial stiffness, and endothelial dysfunction, thereby accelerating the progression of atherosclerotic cardiovascular disease. Genetic studies indicate that Lp(a) concentrations are largely inherited, with limited modulation by lifestyle factors or diet. Conventional lipid-lowering therapies, including statins, ezetimibe, and PCSK9 inhibitors, primarily target LDL-cholesterol but have shown minimal efficacy in lowering Lp(a) levels. This creates a therapeutic gap for patients with persistently elevated Lp(a), who remain at high residual cardiovascular risk despite optimized standard care. Recent advances in RNA interference (RNAi) therapeutics offer a novel strategy to address this unmet need. RNAi allows selective gene silencing at the mRNA level, effectively reducing the production of pathogenic proteins with high specificity. Lepodisiran, a GalNAc-conjugated small interfering RNA (siRNA), exploits this mechanism to selectively target the hepatic LPA gene, which encodes apolipoprotein(a). By inhibiting apo(a) synthesis, Lepodisiran significantly reduces circulating Lp(a) concentrations, providing a durable and targeted approach to cardiovascular risk reduction. Early clinical trials demonstrate that Lepodisiran administration leads to up to 80% reductions in plasma Lp(a), with favorable safety and tolerability profiles. This gene-targeted therapy represents a paradigm shift in CVD management, offering a precision medicine approach for patients with genetically elevated Lp(a) who are unresponsive to conventional therapies. In addition, Lepodisiran may complement existing lipid-lowering treatments, potentially further reducing the incidence of major adverse cardiovascular events (MACE). Overall, RNAi-based Lp(a) reduction represents a promising intervention to fill a critical therapeutic gap, highlighting the evolving role of gene-silencing strategies in modern cardiology and personalized medicine.